On recommendation of NRC, the board of directors of the company, appointed Ms. Hina Patel(M.No-A56541), who is already in employment of the company. She is appointed as a company secretary and compliance officer of the company, as Key managerial personnel of the company with effect from 30th May, 2025.

pdf

Concord Biotech Ltd.

29 May 2025, 07:39PM

1666.90

1.91%

Corp. Action

Concord Biotech Ltd - 543960 - Corporate Action-Board approves Dividend

BSE India

The board has recommended dividend of Rs.10.70 per equity share of face value of Rs. 1 per share for the financial year 2024-25, subject to approval by shareholders of the company at the ensuing AGM

pdf

Concord Biotech Ltd.

29 May 2025, 07:28PM

1666.90

1.91%

Result

Concord Biotech Ltd - 543960 - Financial Result

BSE India

Financial result for Q4 and year ended on 31st March, 2025

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	439.27	258.95	329.78	69.6%	33.2%
Operating Profit Qtr	190.42	97.95	134.29	94.4%	41.8%
Net Profit Qtr	140.39	75.92	95.02	84.9%	47.7%
Earning Per Share Adjusted latest Qtr	13.42	7.26	9.08	84.8%	47.8%

* Consolidated data

Detailed Results

Concord Biotech Ltd.

29 May 2025, 07:12PM

1666.90

1.91%

Board Meeting

Concord Biotech Ltd - 543960 - Board Meeting Outcome for Outcome Of Board Meeting Held On …

BSE India

Outcome of Board Meeting held today i.e. Thursday, May 29, 2025- To Audited Financial Results for the quarter and Financial Year ended on March 31, 2025 and to approve other agendas.

pdf

Concord Biotech Ltd.

27 May 2025

1666.90

1.91%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Revised Earning call Intimation. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, we wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the Audited Standalone and Consolidated Financial Results of the Company for the Fourth quarter and year ended 31st March, 2025, scheduled on Friday, 30th May, 2025 at 02:30 P.M. IST. The Earnings Call invite is enclosed for your records.

pdf

Concord Biotech Ltd.

26 May 2025

1666.90

1.91%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, read with Para A of Schedule III thereto, we wish to inform you that the Company has arranged Earnings Call with Investor/Analyst (Participants) to discuss the Audited Standalone and Consolidated Financial Results of the Company for the Fourth quarter and year ended 31st March, 2025, scheduled on Friday, 30th May, 2025 at 04:00 P.M. IST.

pdf

Concord Biotech Ltd.

23 May 2025

1666.90

1.91%

Board Meeting

Concord Biotech Ltd - 543960 - Board Meeting Intimation for Approval Of Audited Financial Statements For …

BSE India

Concord Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve the audited Standalone and Consolidated Financial results of the company for the quarter and year ended March 31, 2025

pdf

Concord Biotech Ltd.

13 May 2025

1666.90

1.91%

Company Update

Concord Biotech Ltd - 543960 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance …

BSE India

Pursuant to Reg 30 of the SEBI(LODR) 2015, this is to inform that CS Prakash Sajnani, vide letter dated 13/05/2025, has tendered his resignation from the post of Company Secretary and compliance officer with effect from 29/05/2025 after closure of working hours.

pdf